Fragment 176-191
Also known as: HGH Fragment 176-191 · HGH Frag · Frag 176-191
Contents
MW
1817.12 Da
Amino Acids
16 AA
Half-Life
30 minutes
Route
SubQ
CAS
221231-10-3
Formula
C78H125N19O23S2
Mechanism of Action
Fragment 176-191 (HGH Frag 176-191) is the C-terminal fragment of human growth hormone corresponding to amino acids 176-191. It is the SAME COMPOUND as AOD-9604 — different names for the identical 16-amino acid peptide.
MECHANISM: Identical to AOD-9604. Retains the lipolytic domain of GH without GH receptor activation. β3-adrenergic receptor activation on adipocytes → cAMP → HSL → triglyceride hydrolysis. No IGF-1 elevation, no diabetogenic effects, no acromegalic changes, no mitogenic risk.
LIPOGENESIS INHIBITION: Blocks de novo fatty acid synthesis.
The "Fragment 176-191" name refers to the amino acid positions in the GH sequence. AOD-9604 was the pharmaceutical development name. Both refer to the same molecule.
Dosing Protocol
Low Dose
███ – ███ mcg/day
Standard Dose
███ mcg/day
High Dose
███ – ███ mcg/day
Dosing protocols are for paid members
Get exact dosing ranges, injection frequency, timing rationale, and reconstitution math.
Get Clinical Access — $79/moFrequency
Once or twice daily SubQ.
Half-Life
30 minutes
Reconstitution Guide
Full reconstitution protocol with BAC water volumes, concentration math, and units-to-draw per dose is available on the Clinical plan.
Unlock reconstitution guide →Clinical Warnings
Same compound as AOD-9604.
Not FDA approved.
Limited human data.
No muscle/bone anabolic effects — pure lipolytic.
WADA prohibited.
Contraindications
Absolute
Pregnancy
Active cancer
Relative Cautions
Diabetes
Thyroid disorders
Side Effect Profile
Mild
- ●Injection site irritation
- ●Mild headache
Moderate
- ●Nausea
- ●Drowsiness
Synergistic Peptides
Common Stacks
AOD-9604
CJC-1295
Research Status
Same as AOD-9604. PMID 11713213 (Heffernan 2001): hGH fragment lipolysis in obese. TGA GRAS oral formulation. Limited human RCT data.
Frequently Asked Questions
How does Fragment 176-191 work?
Fragment 176-191 (HGH Frag 176-191) is the C-terminal fragment of human growth hormone corresponding to amino acids 176-191. It is the SAME COMPOUND as AOD-9604 — different names for the identical 16-amino acid peptide. MECHANISM: Identical to AOD-9604. Retains the lipolytic domain of GH without GH receptor activation. β3-adrenergic receptor activation on adipocytes → cAMP → HSL → triglyceride hydrolysis. No IGF-1 elevation, no diabetogenic effects, no acromegalic changes, no mitogenic risk. L
What is the standard dose of Fragment 176-191?
Fragment 176-191 dosing protocols are available with a ClinPep Clinical subscription. Dosing varies by indication and patient factors — consult a licensed healthcare provider. General frequency: Once or twice daily SubQ.
What is the half-life of Fragment 176-191?
The half-life of Fragment 176-191 is 30 minutes. This determines optimal dosing frequency and timing.
Who should not use Fragment 176-191?
Fragment 176-191 is absolutely contraindicated in: Pregnancy; Active cancer. Use with caution in: Diabetes; Thyroid disorders.
What are the side effects of Fragment 176-191?
Common mild side effects include: Injection site irritation, Mild headache. Moderate effects: Nausea, Drowsiness.
What peptides stack well with Fragment 176-191?
Fragment 176-191 is commonly stacked with: AOD-9604, CJC-1295, Ipamorelin.
How do you reconstitute Fragment 176-191?
Fragment 176-191 is reconstituted with bacteriostatic water. Exact volumes, concentrations, and units-to-draw calculations are available in the ClinPep Clinical plan. Always follow your compounding pharmacy's instructions.
How long should you cycle Fragment 176-191?
Fragment 176-191 cycle protocols vary by indication. Detailed cycle length, on/off schedules, and monitoring guidelines are available with ClinPep Clinical access. Consult your healthcare provider for personalized cycling guidance.
References & Citations
1 PubMed studies · 0 clinical trials
Effects of human GH and its lipolytic fragment on lipid metabolism
Heffernan M et al.. Int J Obes. 2001
Symptom Indications
Full Clinical Access
Complete Fragment 176-191 Protocol
Access reconstitution math, cycle guides, drug interaction checker, stack builder with contraindication analysis, symptom checker, and downloadable PDF handouts.
Secure payment powered by Stripe.
This information is for educational and research reference purposes only. ClinPep does not provide medical advice, diagnosis, or treatment recommendations. All protocols should be reviewed by a licensed healthcare provider.